Aminoglycosides: Perspectives for Clinical Use in Russia | CMAC

Aminoglycosides: Perspectives for Clinical Use in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(3):260-269

Section
Type
Journal article

Abstract

The susceptibility to aminoglycoside antimicrobials of Gram-negative nosocomial pathogens in Russia and mechanisms of aminoglycoside resistance has been studied. The production of aminoglycoside-modifying enzymes remains to be the major mechanism of aminoglycoside resistance in Russia. High resistance rates to gentamicin and tobramycin were determined by production of enzymes ANT(2″) and AAC(3)-V. Resistance to amikacin was associated with APH(3′)-VI; this enzyme was noted to be highly prevalent in Acinetobacter spp. and Enterobacteriaceae. Interesting that netilmycin remains active against number of gentamicin- and amikacin-resistant isolates of Acinetobacter spp. and Enterobacteriaceae.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared